Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Abstract

Background Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-type tumours, including those with NRAS mutations. We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BRAF-mutated advanced melanoma. Methods In our open-label, non-randomised, phase 2 study, we assigned patients with NRAS-mutated or BRAF-mutated advanced melanoma to one of three treatment arms on the basis of mutation status. Patients were enrolled at university hospitals or private cancer centres in Europe and the USA. The three arms were: twice-daily MEK162 45 mg for NRAS-mutated melanoma, twice-daily MEK162 45 mg for BRAF-mutated melanoma, and twice-daily MEK162 60 mg for BRAF-mutated melanoma. Previous treatment with BRAF inhibitors was permitted, but previous MEK inhibitor therapy was not allowed. The primary endpoint was the proportion of patients who had an objective response (ie, a complete response or confirmed partial response). We report data for the 45 mg groups. We assessed clinical activity in all patients who received at least one dose of MEK162 and in patients assessable for response (with two available CT scans). This study is registered with ClinicalTrials.gov, number NCT01320085, and is currently recruiting additional patients with NRAS mutations (based on a protocol amendment). Findings Between March 31, 2011, and Jan 1…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70024-x

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 0 references

Research works printed but not linked: 4

  1. Hill, 1984, Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A), Cancer, 53, 1299, 10.1002/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4 · doi:10.1002/1097-0142(19840315)53:6<1299::aid-cncr2820530613>3.0.co;2-4
  2. Trefzer, 2011, BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma, Pigment Cell Melanoma Res, 24, 1020
  3. Kim, 2011, A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor, Pigment Cell Melanoma Res, 24, 1021
  4. Flaherty, 2011, Phase I/II study of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor, Pigment Cell Melanoma Res, 24, 1022

Cited by

See all 640

Metadata

Authors
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., Niazi, F., Wandel, S., Peters, M., Zubel, A., & Dummer, R.
Affiliations
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Essen University Hospital (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • St. Luke's Hospital (US)
  • Radboud University Medical Center (NL)
  • Ospedale Policlinico San Martino (IT)
  • The Netherlands Cancer Institute (NL)
  • University Hospital Schleswig-Holstein (DE)
  • Highlands Oncology Group (US)
  • Novartis (Switzerland) (CH)
  • University Hospital Zurich (CH)
Corresponding author
Dummer, Reinhard
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2013-03
Volume
14
Issue
3
Pages
249-256
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2154841567
Cited by
640
References
0
Citations by year
2026: 10 · 2025: 11 · 2024: 24 · 2023: 24 · 2022: 36 · 2021: 37 · 2020: 28 · 2019: 47 · 2018: 43 · 2017: 67 · 2016: 77 · 2015: 88 · 2014: 104 · 2013: 40
FWCI
46.32
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
MEK162, advanced melanoma, NRAS mutation, BRAF V600 mutation, MEK inhibitors, targeted therapy, objective response, acneiform dermatitis, BRAF inhibitors, treatment-emergent adverse events, melanoma-specific mortality
MeSH terms
Aged, Benzimidazoles, Drug Administration Schedule, Europe, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Neoplasm Staging, United States, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70024-x
The paper
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., Niazi, F., Wandel, S., Peters, M., Zubel, A., & Dummer, R. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70024-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.